Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| 9653 | ETCTN | Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Unrothelial Carcinoma of the Bladder | Adult CIRB - Early Phase Emphasis | Completed | |
| 9671 | ETCTN | Exceptional Responders Pilot study: Molecular profiling of tumors from cancer patients who are Exceptional responders | Adult CIRB - Early Phase Emphasis | Completed | |
| 9672 | ETCTN | A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus | Adult CIRB - Early Phase Emphasis | Completed | |
| 9673 | ETCTN | PART A: A Multi-Institutional Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal PART B: A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 9676 | ETCTN | A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 9681 | ETCTN | A Phase 1 Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors. | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 9706 | ETCTN | Randomized phase II study to assess the role of Nivolumab as single agent to eliminate minimal residual disease and maintain remission in acute myelogenous leukemia (AML) patients after chemotherapy (REMAIN Trial) | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 9742 | ETCTN | Multicenter Phase II Study of Nivolumab in Previously Treated Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma | Adult CIRB - Early Phase Emphasis | Completed | |
| 9767 | ETCTN | An Open Label; Multicenter; Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor; MLN0128 (TAK-228); in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation | Adult CIRB - Early Phase Emphasis | Available to Open | |
| 9775 | ETCTN | A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL) | Adult CIRB - Early Phase Emphasis | Available to Open |